Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Purchases of Investments

Cash used to buy marketable securities and other investments.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments turns positive

Q1 FY2026 purchases of investments was $0, compared with -$43.33M a year earlier. Trailing-twelve-month purchases of investments was -$69.05M. Over 3 fiscal years it compounded at -31.5% a year.

Context

  • Purchases of investments amounted to 52.0% of revenue in FY2025, down 131.5 pp from a year earlier.
  • Purchases of investments grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly purchases of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$17.26M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$112.38M-69.2% YoY
LTMMar 2026
-$69.05M-79.2% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-69.2%——
3-year CAGR-31.5%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(112.38M) USD
Year-over-year change
+69.2%

Purchases of Investments vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's LTM Mar 2026 purchases of investments of $69.05M is the 8th largest of the 11 companies compared; the peer median is $99.24M.
  • Its year-over-year change of -79.2% is the 7th highest of 8, against a peer median of -52.5%.
  • Purchases of investments amounts to 31.7% of revenue for VNDA, versus a peer median of 137.6%.
VNDA Competitors Peer median
Purchases of Investments for VNDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$133.5B +92.9%+9.8%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$233.85M -43.9%-19.7%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$189.73M -42.6%-17.7%—
IMRXImmuneering CorporationLTM Mar 2026$160.59M —+20.9%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$100.45M -70.3%+34.7%275.2%
SGMTSagimet Biosciences Inc.LTM Mar 2026$98.04M -52.5%+37.1%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$73.42M -82.6%-13.9%1279.5%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$69.05M -79.2%-31.5%31.7%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$22.55M -56.0%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 ——0.0%
HUMAHumacyte, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding VNDA) $99.24M-52.5%+9.8%137.6%

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Depreciation & Amortization2.84M2.73M3.01M8.13M(950K)
Deferred Income Tax6.75M1.13M(1.29M)(6.48M)81.44M
Stock-Based Compensation15.37M16.28M14.04M12.43M9.47M
Change in Working Capital2.74M6.07M(747K)(6.56M)8.31M
Accounts Receivables(2.47M)(1.09M)(707K)(13.01M)(7.46M)
Inventory(2.23M)(4.48M)(771K)(29K)(3.47M)
Accounts Payables3.04M11.79M(10.98M)1.71M15.82M
Other Working Capital4.4M(151K)11.72M4.78M3.42M
Other Non-Cash Items3.37M(507K)(4.73M)(4.38M)12.76M
Operating Cash Flow64.21M31.98M12.8M(15.76M)(109.44M)
Capital Expenditures(552K)(679K)(383K)(490K)(998K)
Acquisitions (Net)00(100.67M)(4.23M)0
Purchases of Investments(420.46M)(349.26M)(512.61M)(364.77M)(112.38M)
Sales of Investments344.32M399.86M601.6M352.06M208.24M
Other Investing Activities00000
Investing Cash Flow(76.7M)49.93M(12.06M)(17.43M)94.86M
Debt Repayment000(155K)(1.99M)
Common Stock Issued3.55M734K000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0000(915K)
Financing Cash Flow3.55M734K0(155K)(2.91M)
Effect of Forex Changes(85K)315K47K(163K)126K
Net Change in Cash(9.02M)82.96M792K(33.51M)(17.36M)
Free Cash Flow63.66M31.31M12.42M(16.25M)(110.44M)

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.